 
 |
|
Presentations of Cempra Pharmaceutical's CEM-102(fusidic acid)at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
Date: October 29, 2009
Client: Cempra Pharmaceuticals
Summary: CHAPEL HILL, N.C., Oct. 29 /PRNewswire/ -- Cempra Pharmaceuticals today announced data presentations of its lead antibiotic candidate, CEM-102 (fusidic acid), at the Infectious Diseases Society of America, 47th Annual Meeting, Oct. 29 to Nov. 1, 2009, in Philadelphia.
|
|
|
|
|
|
|
Data Presented on Cempra Pharmaceutical's CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
Date: October 29, 2009
Client: Cempra Pharmaceuticals
Summary: CHAPEL HILL, N.C., Oct. 29 /PRNewswire/ -- Cempra Pharmaceuticals today announced a presentation on its novel fluoroketolide antibiotic, CEM-101, at the Infectious Diseases Society of America, 47th Annual Meeting, October 29 to November 1, 2009, in Philadelphia.
|
|
|
|
 |
|
New Data From Arena Pharmaceuticals' Pivotal BLOSSOM Trial of Lorcaserin Demonstrate Improvements in Patients' Body Composition, Cardiovascular Risk Factors and Quality of Life
Date: October 27, 2009
Client: Arena Pharmaceuticals, Inc.
Summary: WASHINGTON, Oct 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings add to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients.
|
|
|
|
|
|
|
Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
Date: October 25, 2009
Client: Arena Pharmaceuticals, Inc.
Summary: WASHINGTON, Oct 25, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported that data from the pivotal BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) Phase 3 trial demonstrate lorcaserin significantly increased excess weight loss, improved markers of cardiovascular risk and glycemic parameters, and was not associated with depression or suicidal ideation. Additional subgroup analyses showed that lorcaserin caused the greatest improvements in lipid profiles, glycemic parameters and other markers of cardiovascular risk in patients in the highest risk categories. The new data were presented at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society.
|
|
|
|
 |
|
Cohera Medical, Inc. Receives Approval To Begin Human Clinical Trials of TissuGlu(R) in Europe
Date: October 23, 2009
Client: Cohera Medical, Inc.
Summary: PITTSBURGH, Oct. 23 /PRNewswire/ -- Cohera Medical, Inc. announced today that it has received approval to begin human clinical trials of its lead product TissuGlu® in Germany. Receipt of the approval allows Cohera Medical to proceed with patient recruitment and initiation of an investigational study of the company's novel internal surgical adhesive being developed for its first intended use to adhere surgical tissues together in large flap surgeries.
|
|
|
|
|
|
|
Cempra Pharmaceuticals Will Present New Data on cem-101 and cem-102 at the Infectious Disease Society Of America, 47th Annual Meeting
Date: October 22, 2009
Client: Cempra Pharmaceuticals
Summary: CHAPEL HILL, N.C., Oct. 22 /PRNewswire/ -- Cempra Pharmaceuticals today announced its schedule of oral and poster presentations at the Infectious Disease Society of America, 47th Annual Meeting, in Philadelphia on Oct. 29 to Nov. 1, 2009.
|
|
|
|
 |
|
Pluristem Therapeutics Will Chair a Panel Presentation on Placenta-Derived Adult Stem Cells at the World Conference on Regenerative Medicine
Date: October 20, 2009
Client: Pluristem Therapeutics Inc.
Summary: HAIFA, Israel--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that it will chair a panel entitled: “Placenta-Derived Adult Stem Cells as an Allogeneic Alternative to Mesenchymal Stromal Cells (MSCs)” at the World Conference on Regenerative Medicine at the Congress Center Leipzig, in Leipzig, Germany. Edwin M. Horwitz, M.D., Ph.D., chairman of Pluristem’s scientific advisory board, will present, as the keynote speaker, the clinical landscape of MSCs and Pluristem’s clinical trial for the treatment of critical limb ischemia (CLI), an example of non-HLA matched allogeneic local delivery of placenta-derived MSCs, at 10:45 a.m. CET, Oct. 30, 2009.
|
|
|
|
 |
|
Ardea Biosciences Announces Additional Positive Results from a Phase 2a Study of RDEA594 at the 2009 ACR/ARHP Annual Scientific Meeting
Date: October 19, 2009
Client: Ardea Biosciences, Inc.
Summary: SAN DIEGO, Oct 19, 2009 (BUSINESS WIRE) -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. These results, as well as data from a preclinical drug-drug interaction study demonstrating RDEA594's potential to be used in combination with allopurinol and febuxostat (Uloric(R), Takeda Pharmaceutical Company Limited; Adenuric(R), Ipsen), are being presented today at the 2009 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting in Philadelphia, Pennsylvania.
|
|
|
|
|
|
|
Pluristem Therapeutics Will Present at the New England-Israel Life Sciences Summit
Date: October 14, 2009
Client: Pluristem Therapeutics Inc.
Summary: HAIFA, Israel--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM:PSTI)(DAX:PJT) today announced that it will present at the New England-Israel Life Sciences Summit at the Brandeis International Business School in Waltham, Mass. Zami Aberman, chairman and CEO of Pluristem will present an update on the company and an overview of its technology at 9:40 EDT, Oct 27, 2009.
|
|
|
|
 |
|
Helix BioPharma's L-DOS47 to be Highlighted at Pharmaceutical Industry Conference
Date: October 14, 2009
Client: Helix BioPharma Corp.
Summary: AURORA, Ontario, Oct. 14 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) today announced that a presentation on L-DOS47 formulation and analytical method development will be made at the "Formulation Strategies for Protein Therapeutics" conference to be held on October 13 to 15, 2009, in Raleigh, North Carolina. The conference is sponsored by IBC Life Sciences.
|
|
|
|
 |
|
Ipsen and Debiopharm Group announce that Decapeptyl® (triptorelin embonate) 6-month successfully completes the European Decentralised Procedure for the treatment of locally advanced or metastatic prostate cancer
Date: October 13, 2009
Client: Debiopharm Group
Summary: Lausanne (Switzerland) and Paris (France), 13 October 2009 - Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical Group, announced that the 6-month sustained-release formulation of Decapeptyl® (1) (triptorelin embonate (2) 22.5 mg) successfully completed its European decentralised registration procedure involving nine countries: Germany (reference member state), France, Austria, Finland, Norway, Belgium, Denmark, Spain and The Netherlands.
|
|
|
|
 |
|
MicroRNA Biomarkers Provide Reliable Diagnosis from Blood Samples
Date: October 13, 2009
Client: febit
Summary: LEXINGTON, Mass. and HEIDELBERG, Germany, Oct. 13, 2009 – Data published in BMC Cancer and PLoS ONE show that microRNA (miRNA) biomarkers provide reliable and highly differentiated diagnosis from blood samples for lung cancer and multiple sclerosis. The invasive and often painful procedure of collecting patient tissue samples may become obsolete in the coming years.
|
|
|
|
 |
|
Louisville's GlobeImmune making strides with therapies for cancers, infectious diseases -- Alicia Wallace
Date: October 12, 2009
Client: GlobeImmune
Summary: LOUISVILLE -- The average survival rate for people who have pancreatic cancer is 5.5 percent. The National Cancer Institute estimates that 42,470 people will be diagnosed with the deadly cancer this year. The Center for Disease Control notes that 3.2 million people in the United States have chronic hepatitis C virus infection. Of every 75 to 85 people with chronic hepatitis C, more than 80 percent will develop chronic liver disease, more than 6 percent will develop cirrhosis and at least 1 percent will die from cirrhosis.
|
|
|
|
 |
|
Arena Pharmaceuticals' Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
Date: October 12, 2009
Client: Arena Pharmaceuticals, Inc.
Summary: SAN DIEGO, Oct 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announcedtoday that lorcaserin will be featured in multiple presentations at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society in Washington, DC.
|
|
|
|
 |
|
C-Suite Makes Room For A New Top Exec -- Gary M. Stern
Date: October 9, 2009
Client: Cellular Dynamics
Summary: Move over CFOs, COOs and CMOs. There's another top honcho entering the C-suite. Hiring chief commercial officers, who integrate sales, marketing, customer service and product development, is on the rise. This may have a big impact on how successful companies are run. Executive search firm Heidrick & Struggles says the number of chief commercial officers or CCOs rose from five in 2001 to 56 in 2008. The number is expected to jump further in 2009. CCOs are proliferating because "CEOs are looking for a single person who can take responsibility, a 'buck stops here' person. CEOs want one person to handle everything for top-line revenue generation and profit," said John Abele, a global managing partner at the executive search firm's office in Cleveland.
|
|
|
|
 |
|
Burnham Institute for Medical Research Expands Scientific Boundaries with Dedication at Lake Nona
Date: October 8, 2009
Client: Burnham Institute for Medical Research
Summary: Orlando, Fla. (October 8, 2009) – Today, Burnham Institute for Medical Research (Burnham) officially dedicated its new 175,000-square-foot scientific facility and marked the opening of Orlando’s Medical City as a life science center. Burnham at Lake Nona is the research anchor for the new development in southeast Orange County and the east coast campus of the La Jolla, Calif.-based institute.
|
|
|
|
 |
|
ACADIA Pharmaceuticals Provides Update on Pimavanserin Collaborative Development Program
Date: October 6, 2009
Client: ACADIA Pharmaceuticals Inc.
Summary: SAN DIEGO--(BUSINESS WIRE)--Oct. 6, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with Biovail Laboratories International SRL (“Biovail”), a subsidiary of Biovail Corporation. Following the announcement on September 1st of disappointing top-line results from the first Phase III PDP trial, ACADIA and Biovail remain committed to the successful development of pimavanserin and have established a development strategy that they believe will strengthen the PDP program. The parties also intend to pursue adjunctive therapy with pimavanserin for schizophrenia as a third indication in the collaboration.
|
|
|
|
|
|
|
Pluristem Therapeutics to Raise $3.0 Million in Registered Direct Offering
Date: October 6, 2009
Client: Pluristem Therapeutics Inc.
Summary: HAIFA, Israel--(BUSINESS WIRE)--Pluristem Therapeutics Inc.. (NasdaqCM:PSTI) (DAX:PJT) today announced that it has entered into definitive agreements with selected institutional investors to sell common stock and warrants for aggregate gross proceeds of approximately $3.0 million, before deducting placement agent fees and estimated offering expenses. The offering includes 2,702,822 shares of common stock and warrants to purchase 1,081,129 shares of common stock. The price per share of Common Stock is $1.12, and the exercise price of the warrants is $1.60. The Warrants will be exercisable for a period of five years commencing six months following the issuance thereof. The closing is scheduled to take place no later than October 12, 2009.
|
|
|
|
 |
|
First Biomarker Experts Workshop in Heidelberg Successful
Date: October 6, 2009
Client: febit
Summary: HEIDELBERG, October 6, 2009 – A panel of more than 30 experts in molecular diagnostics participated in the first workshop of the Biomarker Discovery Center (BDC) held on September 29, 2009 in Heidelberg. Scientist from universities, hospitals and industry presented their recent research on identification and validation of latest-generation biomarkers, discussing the key technological and clinical requirements.
|
|
|
|
|
|
|
Helix Biopharma provides updates on Topical Interferon Alpha-2b and L-DOS47 following pre-IND meeting with the U.S. FDA
Date: October 6, 2009
Client: Helix BioPharma Corp.
Summary: (Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP” / OTCQX: “HXBPF”) today announced progress updates for its ongoing Topical
Interferon Alpha-2b and L-DOS47 product development programs following pre-investigational new drug (“pre-IND”) meetings with the U.S.
Food and Drug Administration (“FDA”).
|
|
|
|
 |
|
GlobeImmune Announces Late-Breaker Presentation of GI-5005 Treatment Response Data at AASLD 2009 Meeting
Date: October 6, 2009
Client: GlobeImmune Inc.
Summary: LOUISVILLE, Colo., Oct. 6, 2009 - GlobeImmune Inc. today announced that a late breaking abstract related to GI-5005, its investigational hepatitis C virus (HCV) product candidate, has been accepted for presentation at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place Oct. 31 through Nov. 4, 2009, in Boston, Mass.
|
|
|
|
|
|
|
The Japanese Cancer Association and Debiopharm Group present the JCA-Mauvernay Award to Dr Ushijima for his oncology research
Date: October 5, 2009
Client: Debiopharm Group
Summary: Lausanne, Switzerland, October 5, 2009 - Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and the Japanese Cancer Association (JCA) presented ‘The JCA-Mauvernay Award’ to Dr Toshikazu Ushijima from the National Cancer Center Research Institute in Tokyo, for his outstanding and innovative research in basic science in the “epigenetic field for cancerization”. The ceremony took place on October 3rd, during the General Assembly of the 68th Annual Conference of the JCA in Japan, where Professor Setsuo Hirohashi, President of the JCA and Dr Rolland-Yves Mauvernay, Founder and President of Debiopharm Group presented him with the Award.
|
|
|
|
 |
|
Corthera's relaxin receives FDA Fast Track designation for the treatment of acute heart failure
Date: October 1, 2009
Client: Corthera Inc.
Summary: SAN MATEO' Calif.' Oct. 1 /PRNewswire/ -- Corthera Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to relaxin, the company's investigational drug for the treatment of acute heart failure (AHF). The Fast Track program facilitates the development and expedites the review of new drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs
|
|
|
|
 |
|
Fovea Pharmaceuticals to be acquired by sanofi-aventis
Date: October 1, 2009
Client: Fovea Pharmaceuticals
Summary: Paris, France – October 1, 2009 – Fovea Pharmaceuticals announced today that it has entered into a binding agreement with sanofi-aventis to sell 100% of its share to sanofi-aventis. Fovea has a portfolio of three clinical compounds, a unique technology platform and several discovery programs dedicated to back of the eye diseases. The deal is valued to a total of €370M, including an immediate upfront payment and subsequent milestone payments related to the progress of the clinical compounds. The closing of the transaction is expected to occur in the 4th quarter of 2009.
|
|
|
|
|
